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 1 
Abstract 2 
 3 
Large blood vessels entering the CNS are surrounded by perivascular spaces that communicate with 4 
the cerebrospinal fluid and, at their termini, with the interstitial space. Solutes and particles can 5 
translocate along these perivascular conduits, reportedly in both directions. Recently, this prompted a 6 
renewed interest in the intrathecal therapy delivery route for CNS-targeted therapeutics. However, 7 
the extent of the CNS coverage by the perivascular system is unknown, making the outcome of drug 8 
administration to the CSF uncertain.   9 
We traced the translocation of model macromolecules from the CSF into the CNS of rats and non- 10 
human primates. Conduits transporting macromolecules were found to extend throughout the 11 
parenchyma from both external and internal (fissures) CNS boundaries, excluding ventricles, in large 12 
numbers, on average ca. 40 channels per mm2 in rats and non-human primates.  The high density and 13 
depth of extension of the perivascular channels suggest that the perivascular route can be suitable for 14 
delivery of therapeutics to parenchymal targets throughout the CNS. 15 
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1 INTRODUCTION 17 
The major problem in developing therapies for diseases involving the CNS is the lack of safe and 18 
efficient means to overcome the blood-brain, blood-cerebrospinal fluid and blood-arachnoid 19 
barriers.1 It has been estimated that for greater than 98% of small molecules and for nearly 100% of 20 
large molecules the brain is not accessible systemically.2 The exclusion of macromolecules from the 21 
CNS is particularly trying because biopharmaceuticals, all of which are large molecules or 22 
supramolecular constructs (proteins3,4,5, oligonucleotides6,7, gene vectors8,9,10), could be particularly 23 
potent as therapies for many diseases involving the CNS11,12,13.  24 
Several avenues of drug delivery to the CNS have been investigated over the last two decades14, 25 
including direct transcranial infusion15 and transport across the blood-brain barrier using endogenous 26 
receptors transporting their ligands (insulin16, transferrin17, lipoproteins18) across the brain 27 
endothelium. Although some preclinical results appear promising19, these studies have not yet 28 
resulted in clinically feasible solutions.  29 
Accumulating evidence suggests that highly potent biopharmaceuticals can exert measurable 30 
biological effects in the CNS after administration to the cerebrospinal fluid (CSF)20,21,22,23,24,25,26, 31 
which renewed the interest in the intrathecal (IT) drug delivery route. Presently, the IT route is 32 
primarily employed in pain and spasticity management, where bioactive molecules are delivered to 33 
the vicinity of nerve roots and the spinal cord, from which they can reach their respective receptors 34 
by diffusion.27 Biopharmaceuticals cannot freely diffuse from the CNS surface deep into the CNS 35 
parenchyma; their diffusion from the CSF would unlikely result in significant penetration beyond a 36 
few tenths of a millimeter28,29. To date, the only plausible explanation of macromolecule entry into 37 
the CNS appears to be through the perivascular spaces. 38 
The CSF has long been known to communicate with perivascular spaces.30 Peroxidase administered 39 
to the CSF was found not only in the spaces surrounding large blood vessels (Virchow-Robin spaces) 40 
but in the smaller spaces along their branches as well31. The available data32,33,34,35,43 suggest that 41 
perivascular solute entrance into the CNS is by 2-3 orders of magnitude too fast to be diffusion- 42 
driven and is likely facilitated by pulsation of the blood vessels contained in the space36,37. Pulsation 43 
can remix the perivascular space longitudinally or cause solute spread via Taylor dispersion38,39 44 
(similarly, pulsatile waves transmitted from large vessels40 can facilitate solute spread in the CSF33). 45 
An alternative mechanistic hypothesis32 is being debated41. The distal termini of perivascular spaces 46 
lack continuous walls and communicate with the interstitial fluid42, which can explain both the 47 
observed macromolecule accumulation in a variety of parenchymal cells43 and the reported biological 48 
effects20-26.  49 
If macromolecule transport from the CSF into CNS is indeed predominantly perivascular, the 50 
ubiquity of perivascular channels capable of transporting macromolecules is critical for the 51 
accessibility of parenchymal targets.  Therefore, we set out to determine the distribution and 52 
configuration of the perivascular pathways transporting macromolecules.   53 
Although the walls of the perivascular channels can potentially be stained with a variety of dyes, 54 
small molecules administered to the CSF are rapidly cleared to the systemic circulation44 and only a 55 
minute fraction of them can enter the perivascular space (e.g., for left-rotating 56 
[18F]fluorodeoxyglucose the half-clearance time in monkeys is 15 minutes45).  A variety of 57 
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4 
fluorescent macromolecular probes (e.g., lectins) can stain the walls of the perivascular spaces, but 58 
the brightness of the tracer layer is not sufficient for reliable channel counting.   59 
We identified a protein avidly taken up by actively endocytosing cells (perivascular 60 
macrophages31,46) residing in the perivascular spaces. The protein, highly glycosylated for enhanced 61 
endocytosis alpha-N-acetyl glucosaminidase  (rhNAGLU)47 conjugated with a fluorophore, was 62 
administered into the cisternal CSF of rats and rhesus monkeys. After the uptake, rhNAGLU 63 
accumulated in large vesicular compartments of the perivascular macrophages, thus labeling the 64 
macromolecule-transporting conduits. The patterns of the tracer deposition in the CNS were 65 
investigated by fluorescence microscopy in unfixed unstained cryosections. 66 
 67 
 68 
2 MATERIALS AND METHODS 69 
2.1 Preparation of fluorescent tracers.  70 
Proteins were labeled with activated fluorescent dyes (Alexa series, Texas Red and Fluorescein 71 
isothiocyanate) from Thermo/Molecular probes. The labeling procedures were carried out generally 72 
in accordance with the manufacturer’s recommendations, with optimization of protein:dye ratio for 73 
maximal fluorescence intensity per protein mass. Fluorescence was measured on a photon counting 74 
spectrometer (PTI Quantamaster, Photon Technology International/Horiba Scientific, Edison, NJ) at 75 
pH=7.4 for a 10 µl aliquot of the test solution in 3 ml of 0.15 M NaCl buffered with 50 mM sodium 76 
phosphate buffer solution, pH = 7.4). 77 
N-acetylglucosaminidase alpha (rhNAGLU) was kindly provided by Synageva Biopharma (presently 78 
Alexion, New Haven, CT). Activated fluorescent dyes were purchased from Molecular 79 
Probes/ThermoFisher Scientific, Waltham, MA. Other reagents and salts, analytical ACS grade or 80 
higher, were from ThermoFisher Scientific and from Sigma-Aldrich, St. Louis, MO. 81 
For the main experimental and control groups, rhNAGLU was labeled with fluorescein 82 
isothiocyanate (FITC).  One ml of (9.2 mg/ml protein solution was mixed with 0.5 ml of 1 M sodium 83 
carbonate buffer, pH=9.4. Under stirring, 40 µl of 67 mg/ml  FITC solution in dry DMSO were 84 
added by 5 µl aliquots at ambient temperature. After an overnight incubation under stirring at 85 
ambient temperature, the protein was isolated by size exclusion chromatography on Sephadex G25 86 
equilibrated with 0.15 M sodium chloride buffered with 20 mM sodium phosphate, pH=7.4. The 87 
entire high molecular weight fraction was collected (total volume 1.6 ml, protein concentration: 5.75 88 
mg/ml).  For a series of four analogous syntheses, dye content, as determined from the optical 89 
densities at 280 and 495 nm, was 5±1 moiety per protein molecule. Analogous synthesis using Alexa 90 
350 NHS ester at pH=9.0 resulted in a product labeled with 8±2 dye moieties per molecule.  Using 91 
calibration curves of dye emission vs. concentration (excitation 490 and 335 nm, emission 520 and 92 
445 nm, respectively), it was found that Alexa 350 was practically unquenched (90±5% vs. the free 93 
hydrolyzed dye fluorescence), whereas the emission of the protein adduct with multiple FITC 94 
residues was significantly reduced (likely self quenched), 20±2% as compared to a free fluorescein 95 
standard.  As a result, the labeled products had similar brightness (photon•sec-1•protein molecule-1), 96 
which is in agreement with the ca. five-fold lower extinction coefficient of Alexa 350 at the 97 
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excitation maximum, as compared to FITC. For animal studies, the solutions were filtered through a 98 
0.22 µm sterile membrane.  99 
2.2 Preparation of radiotracers. 100 
For labeling with Iodine-124, the solutions of macromolecules, 10 to 25 mg/ml in 0.25 M sodium 101 
phosphate buffer (0.1 ml), were incubated in Pierce Iodogen iodinating tubes (ThermoFisher 102 
Scientific, Waltham, MA) with 0.1-3 mCi (0.01-0.3 ml) of [124I]NaI solution containing 10-3M NaOH 103 
(as received from IBA Molecular (presently Zevacor, Dulles, VA) for 40 min. The product was 104 
desalted on Sephadex G-25 (PD-10 column, GE Healthcare Life Sciences, Marlborough, MA) 105 
equilibrated with sterile saline and analyzed by HPLC (BioRad BioSil 125 column) with UV and 106 
gamma detection. Radiochemical yield was 60-80%, depending on the macromolecule. The 107 
radioactivity was measured on an Atomlab 100 dose calibrator   (Biodex Medical Systems, Shirley, 108 
NY). 109 
For labeling with Zirconium-89, macromolecules were first conjugated with 1-(4- 110 
isothiocyanatophenyl) deferoxamine (Macrocyclics, Plano, TX) in 0.1 M sodium carbonate buffer, 111 
pH=9, at 10 and 1 mg/ml, respectively. After an overnight incubation at ambient temperature, the 112 
reaction mixture was spun at 9,000 g for 10 minutes, and the supernatant was desalted and analyzed 113 
as described above.  [89Zr]Zr oxalate in 1M oxalic acid from IBA Molecular (presently Zevacor, 114 
Dulles, VA) was neutralized with 2 M Na2CO3 and then reacted with the deferoxamine- 115 
macromolecule conjugates in 0.2 M HEPES buffer, pH=7.1 at ambient temperature for 20 minutes. 116 
The products were desalted on PD-10 columns equilibrated with 0.9% NaCl (radiochemical yield: 117 
70-90%).  118 
2.3 Animal studies. 119 
All animal studies were carried out in accordance with protocols approved by the Massachusetts 120 
General Hospital and in accordance with relevant guidelines and regulations.  121 
Protein circulation was studied by positron emission tomography (PET) after intravenous (IV) or 122 
lumbar intrathecal (IT) administration of 89Zr or 124I labeled rhNAGLU. Perivascular delineation was 123 
studied using fluorophore-labeled rhNAGLU. All procedures were carried out under Isoflurane/02 124 
anesthesia, in monkeys with continuous monitoring of heart and breathing rates.  125 
Tracer circulation. Tracer circulation studies were carried out by PET to investigate tracer transport 126 
in vivo and to estimate tracer catabolization rates after uptake by cells in normal Sprague Dawley CD 127 
rats (n=4 for 124I labeled rhNAGLU, N=6 for 89Zr labeled rhNAGLU and in non-human primates (M. 128 
fascicularis), N=4 for 89Zr labeled rhNAGLU and N=1 for 124I labeled rhNAGLU. 129 
IV administration of radiolabeled rhNAGLU in both rats and monkeys was carried out through a 130 
temporary intravenous catheter installed in the tail or saphenous vein, respectively.   131 
IT administration of radiolabeled rhNAGLU for circulation studies in M. fascicularis was carried out 132 
through a pre-installed subcutaneous port equipped with a catheter opening into the CSF at L1-L2.   133 
Radiotracer administration was carried out after the initiation of dynamic PET/CT data acquisition, 134 
which continued for 30 minutes after the injection. Then, whole body static PET/CT images were 135 
acquired at multiple time points, 1 to 72 hours.  136 
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The administered doses of rhNAGLU varied from 1 to 20 mg/kg IV in both rats and monkeys, and 3 137 
mg/animal IT in monkeys. The radionuclide doses were 50 to 200 µCi per animal in rats and 0.4 to 1 138 
mCi per animal in monkeys.  139 
Imaging was carried out using a custom PET/CT imaging system consisting of MicroPET Focus 220 140 
PET scanner (Siemens Medical Solutions USA, Inc., Malvern, PA) and CereTom NL 3000 CT 141 
scanner (Neurologica, MA). The imagers were aligned and equipped with a custom imaging bed 142 
extending through both imagers along the alignment axis, ensuring reliable PET/CT image 143 
registration48. Focus 220 works in 3D mode and features a 22 cm animal opening, axial field of view 144 
(FOV) 7.6 cm and transaxial FOV 19 cm. The scanner’s detection system provided a 2.1 mm spatial 145 
resolution for 124I and 1.7 mm spatial resolution for 89Zr. The energy window of the PET imager was 146 
set for the entire study to 350-650 keV, and the coincidence timing window was set to 6 ns. CereTom 147 
NL 3000 is a 6-slice tomograph with high-contrast resolution of 0.4 mm (developed for human head 148 
imaging in ICU). The image acquisition settings were: tube voltage 100 kV, tube current 5 mA, 149 
resolution 6 s/projection, axial mode with slice thickness of 1.25 mm. Image pixel size was set to 150 
0.49x0.49x1.25 mm. The image sharpness was optimized to soft tissue. CT images were used both 151 
for anatomical reference and attenuation correction of the PET images. PET/CT image co-registration 152 
was carried out manually using ASIProVM software (Siemens/CTI Concorde Microsystems, 153 
Knoxville, TN). 154 
PET raw data acquisition and histogramming were carried out on a Dell Precision PWS690 155 
Workstation (Dell, Inc., Round Lake, TX; 3 GB RAM and 4 Xeon 3.20 GHz processors running under 156 
a 32-bit Windows XP [Microsoft Corp., Redmond, WA]) using Siemens MicroPET 157 
Firmware/Software, release 2.5 (Siemens Medical Solutions, Inc., Malvern, PA). Image 158 
reconstruction was carried out on a raid 5 server (17.9 GB RAM and 8 Xeon 2.4 GHz processors 159 
running under Microsoft Windows Server 2003, Enterprise x64 Edition) using Siemens MicroPET 160 
Firmware/Software, release 2.4.5. All subsequent image processing and analysis were performed 161 
on non-host workstations using the ASIProVM software (Siemens/CTI Concorde Microsystems, 162 
Knoxville, TN) running under 32-bit Windows XP and Inveon Research Workplace 3.0 (Siemens 163 
Medical Solutions, Inc., Malvern, PA) running under 64-bit Windows XP. During raw data 164 
histogramming and image reconstruction, the corrections for isotope decay, detectors dead-time, 165 
random coincidences, and tissue attenuation were applied. The data were reconstructed into the 166 
image matrix with the pixel size of 0.95 mm and fixed slice thickness of 0.8 mm using a 3- 167 
dimensional (3-D) ordered-subset expectation maximization/maximum a posteriori (OSEM3D/MAP) 168 
protocol with the smoothing resolution of 1.5 mm, 9 OSEM3D subsets, 2 OSEM3D and 15 MAP 169 
iterations. The data were also reconstructed with Fourier rebinning 2-D filtered backprojection 170 
(FORE-2DFBP) [49] to ensure that the numerical data derived from OSEM3D/MAP and FORE- 171 
2DFBP reconstructed images were identical and thus excluded possible reconstruction artifacts 172 
(none were identified). FORE-2DFBP was performed with a ramp filter cutoff at the Nyquist spatial 173 
sampling frequency (0.5 mm-1). Whole body images were composed of the acquired single bed 174 
position images with a 12 mm overlap. 175 
The dynamic and static PET images were analyzed to obtain numerical kinetic data for multiple 176 
manually selected regions of interest (ROIs), including CSF reservoirs, whole brain, grey and white 177 
matter areas, cardiac blood pool and major organs. Catabolization (lysosomal depolymerization) rates 178 
of rhNAGLU were estimated by clearance of 124I from [124I]I- rhNAGLU accumulating tissues 179 
(which is preceded by lysosomal protein hydrolysis followed by microsomal deiodination of 180 
iodotyrosine50).  181 
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Perivascular delineation studies with fluorophore-labeled rhNAGLU were carried out in rats and non- 182 
human primates.  183 
Prior to the study, rats from different vendors and of different ages were compared for CNS 184 
autofluorescence. The differences were found to be insignificant, with a somewhat higher incidence 185 
of focal deposition of material fluorescent in both green and red channels (consistent with lipofuscin) 186 
in older animals. In the main experimental and control groups, animals were from Charles River 187 
Laboratories (Shrewsbury, MA, USA), Sprague Dawley CD rats, 330±80 g (N=6 per group in the 188 
main experimental and control groups).  189 
FITC labeled rhNAGLU was administered IT via direct injection into the cisterna magna. Prior to the 190 
injection, rats were inducted with 5.0% of 300 ml/min isoflurane, (Forane, Baxter Healthcare 191 
Corporation, USP). During the injection, the rats were given isoflurane at 1.9-2.5% through a 192 
facemask. FITC labeled rhNAGLU, 50 µl of a 5.75 mg/ml tracer solution in sterile saline, was 193 
injected intrathecally through a 23G needle equipped with a catheter into the cisterna magna. The 194 
catheter line (total internal volume <10 µl) was then flushed with 20 µl of sterile saline. Rats with 195 
signs of damage within the intrathecal space (blood in the CSF, sharply asymmetrical tracer 196 
accumulation in the pia mater) and/or intraparenchymal injection (fluorescence in the longitudinal 197 
axonal tufts in the brainstem) were excluded from the studies. 198 
Two female M. Mulatta scheduled for euthanasia were used to verify the presence of the same 199 
perivascular structures as found in rodents. Seventeen years old primates were selected to determine 200 
whether the perivascular cells remain highly endocytosing with age.  201 
Alexa 350 was used in the monkey studies as a fluorophore instead of fluorescein based on the pilot 202 
data showing widespread lipofuscin autofluorescence in older primate brain; the emission of Alexa 203 
350  (Emmax=445 nm) was found to be outside of the spectrum of lipofuscin autofluorescence. IT 204 
administration of Alexa 350 labeled rhNAGLU was carried out via direct injection into cisterna 205 
magna (guided by computed tomography) through a 23G spinal needle equipped with a T-capped 206 
catheter. The tracer was administered in 1.5 ml of a 6.57 mg/ml solution in sterile saline through the 207 
T-cap. The catheter line (total internal volume <50 µl) was then flushed with 300 µl of sterile saline. 208 
Both rats and monkeys were euthanized 24 hours after the IT administration of fluorophore labeled 209 
rhNAGLU with 100 mg/kg of pentobarbital IV under isoflurane anesthesia.  210 
In two rats and in both monkeys, the CNS vasculature was counterstained with Texas Red. The 211 
animals were heparinized 3 minutes before the euthanasia. The upper body was perfused from the 212 
aortal arch to superior vena cava with 5% dextrose in lactated Ringer solution (in one of the 213 
monkeys, the perfusion was carried out in the opposite direction to stain predominantly veins). The 214 
perfusion was carried out at 7.5±0.5 mm Hg until complete displacement of the blood. Then, Texas 215 
Red, 20 mg/ml in dry acetonitrile, was injected into the inflowing perfusate (50  µl per rat, 500  µl 216 
per monkey). The perfusion continued to fully wash out the unreacted dye (ca. 20 ml in rats, 500 ml 217 
in monkeys).   218 
Cryosectioning. After the euthanasia, the brain and cervical spinal cord were removed and sectioned 219 
coronally into three (rats) or five (monkeys) segments: front, middle and cerebellum with cervical 220 
cord. The segments were fast-frozen on a 0.5” thick aluminum alloy 6061 block (Grainger, Lake 221 
Forest, IL, cat. # 1NYP5) hydrophobised with silicone oil and cooled on dry ice, and embedded in 222 
O.C.T compound (Tissue-Plus  4585, (Scigen Scientific Gardena, CA).  223 
  Preprint 
 
 
8 
The frozen segments were kept at -21oC and cryosectioned on a Leica CM3050 S cryostat (Leica 224 
Biosystems, Buffalo Grove, IL) into coronal (in some instances sagittal) 20 µm slices (CT: -15o C; 225 
OT: -12o C) and 100 µm coronal slices (CT: -11 o C; OT: -10 o C). The cryosections were placed on 226 
25.4x76.2x1mm microscopy slides, air-dried, and covered with 0.17 mm thick cover slips over OCT.  227 
2.4 Photoimaging.  228 
The microscopy slides were imaged on a Nikon Eclipse epifluorescence TE300 microscope equipped 229 
with long working distance objectives (CFI Plan Fluor ELWD 20X and 60X, Plan Fluor 4X and Plan 230 
Achromat 1X). Narrow band filter cubes (high throughput filter sets # 49000, 49009, 49011 from 231 
Chroma Technology, Bellows Falls, VT, USA) and Nikon DS-Qi2 photon counting camera were 232 
used for image acquisition. The dark current of the camera was 395±5 photons•s-1 per well. The three 233 
fluorescence channels were well isolated from each other, with no detectable FITC crosstalk to the 234 
blue and red channels, no detectable Alexa 350 crosstalk to the green and red channels, no detectable 235 
Texas Red crosstalk to the green channel and 0.16±0.21% Texas Red crosstalk to the blue channel.  236 
The images of the CNS cryosections were acquired in all three fluorescence channels, in phase 237 
contrast (X20 and X60) and in bright field with crossed polarizers (X4). Fluorescence background in 238 
all three channels was registered every day using a covered microscopy slide with a layer of OCT. 239 
The images were processed using Nikon Elements AR 4.30.02 software.  240 
For each studied CNS cryosection, a series of 4X frames completely covering the slice was acquired 241 
and merged in one image. Then, 20x and 60x images were acquired from multiple regions.  242 
Sections obtained from the areas corresponding to plates ## 3, 25, 51, 87, 115 and 161 of the Paxinos 243 
atlas51 were used for counting the perivascular channel entering the parenchyma in rats.  In monkeys, 244 
the channel counting was performed in sections made through the middle of the brain, approximately 245 
corresponding to slice 3 in Calabrese et al52, Fig. 3. Identification of sulci was in accordance with 246 
Von Bonin and Bailey53. 247 
Images were used for analysis without further processing.   248 
Images intended for deconvolution were acquired as 3D stacks (2 µm per sub-slice) using Nikon Plan 249 
Apochromate λ 60X Oil objective and processed using Nikon EDF or 3D deconvolution algorithms.  250 
For presentation, images were exported to monochrome TIFF format. Monochrome TIFF images 251 
were pasted into the respective layers of RGB templates to obtain mono- or multicolored images. In 252 
all images and individual RGB channels the LUTs are linear and cover the full range of the data. 253 
Surface intensity plots were produced using Nikon Elements AR software.  254 
2.5 Photoimaging data analysis 255 
The general patterns of the tracer distribution were studied in the whole-slice composite images 256 
manually stitched from 1X (monkey) or 4X images. The detailed patters of perivascular architecture 257 
was investigated in 20X and 60X images from 20 µm cryosections.  258 
Cryosections with counterstained vasculature were used to establish the relative positioning of the 259 
blood vessels and cells accumulating the tracer. The preliminary estimates of the perivascular 260 
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channel counts in various  CNS sections were obtained from images of 20 µm cryosections and 261 
multi-slice image stacks. Only channels with patterned linear probe deposition were counted at their 262 
origins at external and internal boundary layers of the CNS. Patterned perivascular cells were clearly 263 
identifiable (signal to background ratio = 12000±450:50±20 photons•s-1 per well) and distinguishable 264 
from the surrounding parenchyma (pattern to the parenchymal cell ratio = 12000±450:250±100 265 
photons•s-1 per well). 266 
Considering the out-of-plane positioning of some channels, which prevented their recognition in the 267 
thin 20 µm sections, the final counting was carried out in 20X images of 100 µm sections. The 268 
numbers of the characteristic linear patterns formed by the perivascular cells per unit of length of the 269 
respective CNS boundary were calculated and then multiplied by the section thickness to obtain 270 
channel counts per unit of the boundary area.  271 
The same counting technique was applied to the experimental (FITC-rhNAGLU injected) and control 272 
groups of rats, n=6 each. Channel counts were obtained from 248 experimental and 241 control 273 
cryosections. Counting was carried out by four investigators, three of which participated in studying 274 
both experimental and control images. As compared to the control group, this counting approach 275 
provided >99.5% specificity calculated as ratio of channel patterns identified in the experimental and 276 
control groups, 4247 and 19 respectively. All 19 false positive counts were from two control animals 277 
out of six, 15 from one rat and 4 from another.  278 
The channel origination densities (channel•mm2) obtained for each specific CNS boundary were 279 
tabulated, and mean counts and standard deviations were calculated for the experimental and control 280 
groups.  281 
In cryosections obtained from non-human primates, channel counting was carried out analogously at 282 
the external CNS surface and in sulci and fissures. 283 
All original imaging files in Nikon nd2 format (photoimaging), Siemens MicroPET format (PET 284 
imaging) and the numerical data are available upon request.  285 
2.6 Limitations 286 
The limitation of the method relates to the lack of full statistical information on the existence of 287 
macromolecule – transporting perivascular conduits not populated by perivascular macrophages. If 288 
such channels do exist, they were not counted. Analysis of images obtained with co-staining of the 289 
arteries in rodents (perfusion staining with Texas Red) showed that  < 1% of the stained perivascular 290 
channels extending from the CNS surfaces may be unpopulated (2 arteries out of counted 300).  291 
Therefore, although the densities of the perivascular entrances reported in this paper may be 292 
somewhat underestimated (most likely, by not more than single percents), this does not affect the 293 
conclusions of this report.   294 
Small perivenous channels traced from large, morphologically identifiable veins were found to 295 
contain labeled perivascular cells at the very entrances but no highly labeled perivascular 296 
macrophages were identified deeper in the parenchyma.  The available data at this point do not allow 297 
to determine whether there is no significant transport of macromolecules up the perivenous spaces or 298 
there are no cells taking up the tracer in the deep perivenous channels.    299 
 300 
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3 RESULTS 301 
Being a lysosomal protein, rhNAGLU was sufficiently stable after internalization by cells to study its 302 
deposition in the CNS cells 24 hours post administration (Supplement Figure S1), i.e., at the time 303 
when the free protein has been already cleared from the CSF (Figure S2). Consequently, the 304 
background fluorescence was minimal and the tracer deposition patterns were readily discernible in 305 
the CNS of rats and monkeys.  306 
3.1 Rats.  307 
The highest levels of tracer accumulation were found in cells lining the CNS surface (pia mater and 308 
its extensions into the fissures and other internal boundaries) and in some perivascular cells (Figure 309 
1-3). In these cells, fluorescence exceeded the emission of the surrounding cells by up to two orders 310 
of magnitude (see Methods), resulting in high-contrast images of cells and structures accumulating 311 
the tracer. The intracellular vesicular pattern of fluorophore deposition (Figure S3) was in agreement 312 
with endocytosis as the expected mechanism of cell labeling. 313 
Essentially the same levels of tracer deposition were found in the cells lining the internal 314 
(intrafissural) and external CNS boundaries, except for the boundaries of the ventricular system. The 315 
internal boundaries were homogenously fluorescent throughout their entire depth (Figure 1).  316 
Perivascular spaces were found to extend not only from the external but also from the internal 317 
boundaries, excluding the ventricular system (Figure S4). The perivascular spaces around larger 318 
(d>0.1 mm) vessels morphologically identifiable as both arteries and veins were surrounded 319 
by nearly continuous layers of fluorescent cells (Figure 2), in which the tracer concentration 320 
was nearly as high as in the pial cells.  No tracer accumulation was observed within or on the 321 
luminal side of the walls of vessels of any type or size.   322 
Smaller perivascular spaces had a characteristic linear “dotted” pattern of tracer accumulation at their 323 
origins (Figure 3a) first reported by Wagner et al31 (Figure 3b). Such patterns, entering the 324 
parenchyma at angles 70o-90o to the boundary plane (Figures 1, 3, 4 a), were readily identifiable in 325 
all CNS regions except the pineal gland and fissures of the cerebellum.   326 
Co-staining of blood vessels with Texas Red revealed that the regularity of the linear “dotted line” 327 
pattern completely disappeared with vessel branching. Some of the perivascular spaces had single or 328 
irregularly distanced tracer-accumulating cells even at their origin (Figure 4). In the deeper 329 
parenchyma, the regular linear patterns were replaced by irregularly positioned tracer-accumulating 330 
cells. Investigation of sections with co-stained blood vessels showed that most of these cells had a 331 
perivascular location (as in Figure 4 c, 4 d). Other cells possibly belonged to out-of-plane 332 
perivascular channels (Figure 5a).  333 
In the olfactory bulbs (Figure 1a, 5a), 68±24 perivascular channels per mm2 were entering from the 334 
ventral surface, 28±18 mm-2 from the dorsal surface, and 107±14 mm-2 from the boundary between 335 
the bulbs.  Deeper in the bulb, tracer accumulation was primarily in scattered cells, gradually 336 
decreasing in numbers from the glomerular towards the granule cell layer, but present even within the 337 
most medial regions.   338 
In the frontal sections of the brain, the highest density of perivascular channels was in the middle 339 
cleave of basal forebrain (174±145 mm-2) and in the longitudinal fissure (90±19 mm-2).  The basal 340 
c 
c 
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forebrain outside of the cleave had 40±17 channel entrances per mm2. The dorsolateral and 341 
ventrolateral surfaces of the frontal cortex had 31±14 and 27±12 labeled channel entrances per mm2, 342 
respectively. In a section cut through the rostral anterior commissure (Figure 1 b), linear conduits 343 
were observed in the cortex, cingulate cortex, and basal forebrain. Labeling of scattered individual 344 
cells was also noted within the corpus callosum and the deep parenchyma of internal brain structures. 345 
Both scattered and linear-patterned tracer accumulation was especially remarkable within the basal 346 
forebrain.  347 
Farther caudally, linear-patterned and scattered tracer accumulation was present in the neocortex, 348 
hippocampal formation, thalamus, and hypothalamus, as well as in other internal brain structures 349 
(Figure 1c). The highest densities of perivascular entrances, 49±7 mm-2 and 55±16 mm-2, were found 350 
in the longitudinal fissure and the ventral surface of the hypothalamus, respectively.  In the 351 
subhippocampal cistern extending from the quadrigeminal cistern between thalamus and 352 
hippocampus (Figure S6), the observed channel density was 26±243 mm-2. The dorsal and ventral 353 
surfaces of the cortex had densities of 34±16 and 28±10 mm-2, respectively. Scattered fluorescent 354 
cells were present within internal brain structures containing predominantly neuronal bodies 355 
(striatum, thalamus, hypothalamus, globus pallidus), as well as, to a lesser extent, within axonal 356 
structures (corpus callosum, corticofugal pathways, optic tracts, stria medullaris of the thalamus, and 357 
fimbria of the hippocampus). Remarkable linear-patterned tracer deposition was noted at the 358 
boundaries between the dentate gyrus and the superior aspect of thalamus and between the fimbria of 359 
the hippocampus and the superior aspect of thalamus. Linear patterns were also observed in areas 360 
surrounding larger blood vessels and on the inferior aspects of optic tracts. 361 
In the areas of the caudal cerebrum and rostral cerebellum  (Figure 1d, 1e), both linear-patterned and 362 
scattered tracer deposition in the neocortex, entorhinal areas, subiculum, brainstem nuclei and white 363 
matter were evident. Continuous cell layers accumulating the tracer were observed at the boundaries 364 
between the brainstem and pineal gland, the brainstem and cortex, and between the cerebellum and 365 
brainstem.   366 
Scattered cells containing the tracer were present in large numbers throughout the pineal gland and 367 
the interpeduncular nucleus (Figure 5 b). However, no traceable linear patterns were observed, which 368 
may be related to the architecture of the vascular network of these structures that differ from the rest 369 
of the CNS54.  370 
In the midbrain cistern, which in rats is essentially a tight subcortical fissure), channel density was 371 
higher than on the external dorsal and ventral surfaces of the caudal cortex than on the surface of the 372 
thalamus, 43±17 and 41±17 mm-2 vs. 27±13 and 28±11 mm-2, respectively.   373 
In the cerebellum (Figure 1e, 4d, S5), continuous layers of labeled cells within its fissures were 374 
evident. Most of the vessels extending from the fissures through the granular layers towards the 375 
Purkinje layers had only 1 or 2 perivascular cells. Some of the branches that they formed in the 376 
granular layer had tracer-labeled perivascular cells as well (Figure 4 d).  In the cerebellum, the 377 
densities of perivascular entryways on the dorsal and ventral surfaces were 22±12 and 17±11 mm-2, 378 
respectively. In the brainstem, channel densities on the ventral and dorsal (facing cerebellum) 379 
boundaries were 35±12 and 39±16, respectively.  380 
In the spinal cord (Figure 1 f), remarkable linear-patterned labeling along multiple radial channels 381 
was present within the lateral white matter. The average channel densities entering from the dorsal 382 
and ventral surfaces were 20±13 and 29±13 mm-2 respectively. The dorsal and ventral median sulci 383 
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were covered by highly labeled cells and contained 63±66 mm-2 and 59±50 mm-2 channel entries, 384 
respectively.   Labeled cells were scattered throughout the gray matter of the spinal cord as well, but 385 
without detectable linear patterns.  386 
Overall throughout the CNS, the highest density of perivascular entryways, 90±71 mm-2, was found 387 
in the longitudinal fissures and cleaves, whereas at other internal boundaries the channel density was 388 
39±18 mm-2. At the external boundaries (not including olfactory bulbs), the perivascular entryway 389 
density was 28±15 mm-2 (Figure S7). We note that the densities reported in this paper include only 390 
linearly patterned channels identifiable with >99% specificity as compared to the control group 391 
(Methods).   392 
Although tracer penetration from the perivascular channels to the parenchyma was not the focus of 393 
this study, indications of it were clearly present in all studied CNS tissues of rats. Fluorescence 394 
patterns and intensities outside of the perivascular spaces indicated a statistically significant exit of 395 
the tracer from the perivascular channels into the parenchyma (Figure S8). In a group of animals 396 
where fluorescent rhNAGLU was administered systemically (intravenously), no patterns indicating 397 
protein accumulation in any particular cells or cell organelles were detected in the CNS (not shown). 398 
Therefore, the fluorescence patterns resulting from tracer administration to the CSF cannot be 399 
attributed to rhNAGLU uptake from the systemic circulation after tracer clearance from the CSF to 400 
the blood.  401 
3.2 Non-human primates.  402 
Investigation of cryosections from M. mulatta (N=2) has shown that the tracer follows generally the 403 
same route as in rats, from the CSF into the internal boundary layers (all sulci and fissures) and 404 
perivascular channels. The latter were readily identifiable by the same characteristic linear patterns of 405 
tracer endocytosing cells as in rats, with channels originating inside fissures and sulci as well as on 406 
the external surface (Figure 6).  407 
Dynamic PET data55 demonstrated that rhNAGLU (labeled with 89Zr) concentration in the fissures, 408 
sulci and major periarterial conduits (Virchow-Robin spaces) equilibrates with that of the cisternal 409 
CSF within 30 minutes after the tracer administration to the CSF. Tracer penetration into the 410 
parenchymal compartments (outside of fissures, sulci and major perivascular spaces) continues at a 411 
lower rate, reaching maximum at 3±2 hours.  The fast equilibration of the tracer concentration 412 
between the CSF and the intrafissural/sulcal liquid layers is likely a result of the same biomechanical 413 
process (pulsation-assisted remixing/Taylor diffusion) that equilibrates solute concentrations 414 
throughout the CSF. 415 
Thus, the in primates, in spite of the much larger dimensions of the brain and other parts of CNS, the 416 
perivascular liquid system can perform essentially the same transport functions as in rats. Based on 417 
the limited dataset (36  transversal full-brain/spinal cord sections from two animals), we estimate that 418 
channel entrance densities at the external and internal CSF surfaces vary within the range of 419 
approximately 20 to 100 mm-2, with the average for the dataset of 36±22 mm-2. No channels were 420 
found to be extending from the inner surfaces of the ventricles (although scattered tracer 421 
accumulating cells were observed in the vicinity of ventricles as far as 0.2-.03 mm from the surface).   422 
A larger study is needed to quantify the channel origination densities in a statistically significant 423 
manner.  424 
 425 
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4 DISCUSSION  426 
The ubiquity of the perivascular channels accessible for macromolecules administered to the CSF (in 427 
particular, their entrance to the parenchyma from the internal as well as external CNS boundaries) 428 
suggests that the perivascular route can potentially provide a robust avenue for delivery of 429 
biopharmaceuticals and other macromolecules to the CNS. It is especially encouraging that in 430 
primates perivascular transport of macromolecules to the CNS occurs not only from the external 431 
surface, but also from the internal boundaries, from which perivascular spaces extend into deeply 432 
located compartments.  433 
The mechanism of the fast solute entrance into the (thin) internal liquid layers communicating with 434 
the CSF has not been studied. Massive tracer entrance deep into the fissures cannot be explained by 435 
diffusion; it seems logical to suggest that the mechanism of solute transport is active. Both arteries 436 
and veins run within these layers, hence liquid uptake into the fissures could not be driven by a 437 
pressure gradient between the periarterial and perivascular spaces. Pulsatile remixing of the liquid 438 
content of the fissures, not unlike that of the CSF in the leptomeningeal space, seems to be the only 439 
viable explanation of the observed solute transport into the fissures from the CSF.  440 
The data further suggest that macromolecules enter the perivascular spaces surrounding not only 441 
arteries, but also morphologically identifiable (larger) veins. In view of the significant similarities in 442 
the arteriole and venule morphology at high branching levels, protein entrance into small perivenous 443 
spaces could not be positively confirmed within this study and requires further investigation.  444 
The data strongly support the accessibility of CNS to macromolecular and supramolecular 445 
therapeutics delivered to the entrances of perivascular channels leading to the target region.  446 
Previously we have shown that such delivery is possible throughout the entire cerebro-cervical and 447 
spinal CSF pools33,34,35,43.   448 
Detectable labeling of non-perivascular cells confirms that perivascular conduits do communicate 449 
with the parenchymal interstitial fluid, enabling the transport of macromolecules of at least the size of 450 
rhNAGLU (ca. 12 nm for dimer56) to the interstitial space of the CNS. The latter represents about 451 
20% of the CNS volume57 and can provide avenues for further transport of macromolecules to distant 452 
cells.  453 
However, in spite of the fenestrated nature of the terminal perivascular sheaths58, the route as a whole 454 
is not entirely barrier-free: the actively endocytosing perivascular cells that we used in this study to 455 
trace perivascular channels and cells lining the external and internal boundaries of the CNS are 456 
positioned along the route and may intercept any solutes that can bind their endocytosis-mediating 457 
receptors. A study on the receptor specificity of these cells would enable developing therapeutics that 458 
can reach the parenchymal cells more efficiently.  459 
The similarities in the configuration and densities of the perivascular conduits transporting 460 
macromolecules in primates and rats suggest that rodents are potentially suitable for modeling the 461 
transport of intrathecally administered macromolecular and supramolecular therapeutics. However, 462 
quantitative evaluation of all stages of the transport process, especially the stages of entrance from 463 
the perivascular space to the interstitial space (of which little is known) is necessary for direct 464 
scaling.    465 
In conclusion, our data support the hypothesis that perivascular conduits can transport 466 
macromolecules to most, if not all, subcompartments of the CNS. Further mechanistic investigation 467 
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of the physiological transport processes in the CSF and in perivascular space, as well as investigation 468 
of the functions of the perivascular cells, are required to develop therapeutics optimized for IT 469 
administration. Investigation of the above factors will also benefit our understanding of the transport 470 
and clearance of endogenous products of CNS59,60 and interstitially (CNS) administered 471 
therapeutics61.  472 
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FIGURES 514 
Figure 1.  515 
Deposition of FITC-rhNAGLU in the CNS of rat, 24 hours after administration to cisternal CSF. 516 
Unstained, unfixed coronal 20 µm cryosections. a. Olfactory bulbs. b. Brain section at the level of 517 
rostral anterior commissure. c. Brain section through hippocampal formation and thalamus. d. Brain 518 
section through pineal gland.  e.   Cerebellum and brainstem section ca. 0.5 mm rostral of the facial 519 
nerves. f. Section through cervical spinal cord. See Methods for section reference to Paxinos atlas51. 520 
Field of view: A: 8.8x5.9 mm, B-E: 17.7x11.8 mm, F: 4.4x2.9 mm 521 
  522 
   Preprint 
 
17 
Figure 2.   523 
FITC-rhNAGLU accumulation (green) around major blood vessels (red) in the perivascular spaces 524 
extending from the subhippocampal cistern. Unstained unfixed 20µm sagittal cryosection 3 mm off 525 
the central plane, 0.9 x 0.6 mm (See Figure S 6 for the anatomical context). 526 
 527 
 528 
  529 
  Preprint 
 
 
18 
Figure 3.   530 
a. Small regularly labeled perivascular space extending from the surface of the frontal cortex, 0.6x0.4 531 
mm.  b. From [31]: analogous perivascular space, peroxidase/3,3'-diaminobenzidine staining. c. 532 
Irregularly labeled perivascular channel in the cerebellum, 0.9 x 0.6 mm. a, c: unstained unfixed 533 
20µm coronal cryosections. Red: blood vessel extending from a cerebellar fissure. 534 
 535 
 536 
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Figure 4.   537 
Morphology of perivascular conduits (green: FITC-rhNAGLU, red: blood vessels stained with 538 
Texas Red, cyan: cell nuclei stained with Hoechst 33342). a. Frontal cortex, vessel entrance from 539 
the external surface of the brain; 0.6 x 0.4 mm, sagittal plane.  b. Conduits (horizontal linear 540 
patterns) extending from the longitudinal fissure (vertical line in the center), 0.9 x 0.6 mm, coronal 541 
plane. c. Scattered labeling of internal perivascular spaces in caudate putamen; sagittal plane, 542 
0.3x0.2 mm. d. Cerebellar fissure and perivascular spaces extending through the molecular cell 543 
layer to the Purkinje cells and granular cell layers, 0.9 x 0.6 mm, coronal plane. Unstained, unfixed 544 
20 µm cryosections. 545 
 546 
 547 
 548 
  549 
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Figure 5.   550 
a. Perivascular channel at the dorsal surface of olfactory bulb (green); blood vessels stained with 551 
Texas Red; 0.9 x 0.6 mm; sagittal slice.  b. Pineal gland: non-linear pattern of tracer deposition; 0.9 x 552 
0.6 mm, transverse slice; no co-staining.    553 
 554 
 555 
 556 
  557 
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Figure 6.  558 
Labeling of perivascular channels with Alexa-350-rhNAGLU in monkey (M. fascicularis). a. 559 
Perivascular cells around arteries branching from the arcuate sulcus (AS) and entering cortex from its 560 
surface (CS), 4.4x2.9 mm.  b. Perivascular channels branching from the anterior subcentral sulcus 561 
(SAS), 3 x 2 mm. 100 µm cryosections. 562 
 563 
 564 
 565 
 566 
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